Research Article

Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management

Volume: 89 Number: 3 August 14, 2026
EN

Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management

Abstract

Objective: This retrospective cohort study evaluated the efficacy, safety, and functional outcomes of percutaneous cryoablation in T1a renal cell carcinoma (RCC), with an emphasis on residual disease management and radiological follow-up.

Materials and Methods: Thirteen patients with 15 T1a RCC lesions treated with percutaneous cryoablation between September 2023 and June 2024 were retrospectively analyzed. Clinical and follow-up data were collected. All procedures were performed under CT and US guidance using a standardized double freeze–thaw protocol. Follow-up included renal function assessment and radiological imaging with MRI or CT at the 3rd month, 6th month, and 1 year.

Results: The study included 11 males (84.6%) and 2 females, with a median age of 62 years (range, 50-71 years). The median tumor diameter was 22 mm, and the PADUA score was 8. The median number of cryoablation probes used per procedure was 2 (range, 1-3), and the median procedural time was 60 minutes. Complete ablation was achieved in most patients; however, residual disease was detected in three patients during follow-up. Among those with residual disease, one underwent repeat cryoablation, one underwent surgery, and one underwent active surveillance. Complications were minor, including a single hematoma and one intracystic hemorrhage, both of which were asymptomatic. Renal function was preserved throughout the follow-up period, including in solitary kidney patients, with no clinically significant eGFR decline.

Conclusion: Percutaneous cryoablation achieved local tumor control with preservation of renal function and a low complication rate during follow-up in patients with T1a RCC.

Keywords

References

  1. Woon D, Qin S, Al-Khanaty A, Perera M, Lawrentschuk N. Imaging in renal cell carcinoma detection. Diagnostics 2024;14(18):2105. google scholar
  2. Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER- based study. Clin Genitourin Cancer 2019;17(1):46-57.e5. google scholar
  3. Bellin MF, Valente C, Bekdache O, Maxwell F, Balasa C, Savignac A, et al. Update on renal cell carcinoma diagnosis with novel imaging approaches. Cancers 2024;16(10):1926. google scholar
  4. Wang L, Guer M, Puri D, Liu F, Dhanji S, Meagher MF, et al. Characteristics and outcomes of T1a renal cell carcinoma presenting with metastasis. Cancers 2025;17(3):364. google scholar
  5. Young M, Jackson-Spence F, Beltran L, Day E, Suarez C, Bex A, et al. Renal cell carcinoma. Lancet 2024;404(10451):476-91. google scholar
  6. Bex A, Ghanem YA, Albiges L, Bonn S, Campi R, Capitanio U, et al. European Association of Urology guidelines on renal cell carcinoma: The 2025 update. Eur Urol 2025;87(6):683-96. google scholar
  7. Simmons MN, Fergany AF, Campbell SC. Effect of parenchymal volume preservation on kidney function after partial nephrectomy. J Urol 2011;186(2):405-10. google scholar
  8. Bertolotti L, Bazzocchi MV, Iemma E, Pagnini F, Ziglioli F, Maestroni U, et al. Radiofrequency ablation, cryoablation, and microwave ablation for the treatment of small renal masses: efficacy and complications. Diagnostics 2023;13(3):388. google scholar

Details

Primary Language

English

Subjects

Oncologic Surgery, Radiology and Organ Imaging

Journal Section

Research Article

Publication Date

August 14, 2026

Submission Date

January 14, 2026

Acceptance Date

May 11, 2026

Published in Issue

Year 2026 Volume: 89 Number: 3

APA
Çakır, M. S., Teke, İ., Ercan, C. C., Erdem, S., Şanlı, M. Ö., Özcan, F., & Acunas, B. (2026). Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management. Journal of Istanbul Faculty of Medicine, 89(3), 154-162. https://doi.org/10.26650/IUITFD.1863207
AMA
1.Çakır MS, Teke İ, Ercan CC, et al. Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management. İst Tıp Fak Derg. 2026;89(3):154-162. doi:10.26650/IUITFD.1863207
Chicago
Çakır, Mehmet Semih, İlker Teke, Celal Caner Ercan, et al. 2026. “Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management”. Journal of Istanbul Faculty of Medicine 89 (3): 154-62. https://doi.org/10.26650/IUITFD.1863207.
EndNote
Çakır MS, Teke İ, Ercan CC, Erdem S, Şanlı MÖ, Özcan F, Acunas B (August 1, 2026) Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management. Journal of Istanbul Faculty of Medicine 89 3 154–162.
IEEE
[1]M. S. Çakır et al., “Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management”, İst Tıp Fak Derg, vol. 89, no. 3, pp. 154–162, Aug. 2026, doi: 10.26650/IUITFD.1863207.
ISNAD
Çakır, Mehmet Semih - Teke, İlker - Ercan, Celal Caner - Erdem, Selçuk - Şanlı, Mehmet Öner - Özcan, Faruk - Acunas, Bulent. “Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management”. Journal of Istanbul Faculty of Medicine 89/3 (August 1, 2026): 154-162. https://doi.org/10.26650/IUITFD.1863207.
JAMA
1.Çakır MS, Teke İ, Ercan CC, Erdem S, Şanlı MÖ, Özcan F, Acunas B. Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management. İst Tıp Fak Derg. 2026;89:154–162.
MLA
Çakır, Mehmet Semih, et al. “Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management”. Journal of Istanbul Faculty of Medicine, vol. 89, no. 3, Aug. 2026, pp. 154-62, doi:10.26650/IUITFD.1863207.
Vancouver
1.Mehmet Semih Çakır, İlker Teke, Celal Caner Ercan, Selçuk Erdem, Mehmet Öner Şanlı, Faruk Özcan, Bulent Acunas. Percutaneous Cryoablation of T1A Renal Cell Carcinoma: Functional Outcomes and Residual Disease Management. İst Tıp Fak Derg. 2026 Aug. 1;89(3):154-62. doi:10.26650/IUITFD.1863207

Contact information and address

Addressi: İ.Ü. İstanbul Tıp Fakültesi Dekanlığı, Turgut Özal Cad. 34093 Çapa, Fatih, İstanbul, TÜRKİYE

Email: itfdergisi@istanbul.edu.tr

Phone: +90 212 414 21 61